Compare Immunovant Inc. Common Stock (IMVT) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Starbucks Corp — how do they compare? Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B), while Starbucks Corp trades at $90.75 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 17× Immunovant Inc. Common Stock's market cap, and Starbucks Corp pays a 2.7% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Starbucks Corp for 190 Days on average.
| IMVT | SBUX | |
|---|---|---|
Market Cap | $6.25B | $106.26B |
Volume | 1,755,411 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $108.55 |
52-Week Low | $17.03 | $78.46 |
Typical Hold Time | 1 Days | 190 Days |
Enterprise Value | $5.35B | $125.08B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Starbucks (SBUX) trades at $93.21, down 0.4% on the day, amid a bearish technical signal and recent store closure announcements. The stock shows mixed earnings performance with Q1 and Q2 2026 beats but a Q4 2025 miss, while 2025 revenue grew to $37.18B with a net income margin of 5.17%. Analyst consensus is a Buy with a $115.50 price target, but technical indicators suggest near-term pressure with support at $89 and resistance at $96.
The outlook for SBUX hinges on its turnaround strategy execution, including portfolio optimization through store closures. Upside potential exists from analyst targets, but risks include labor relations, competitive pressures, and macroeconomic sensitivity. The stock's high P/E of 53.88 indicates growth expectations must be met for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
